Loading
LYN is a SRC-family kinase that sits under the B-cell receptor; dasatinib and bosutinib inhibit it alongside BCR-ABL, and LYN over-activity is one way chronic myeloid leukaemia escapes imatinib.
LYN is a SRC-family tyrosine kinase expressed in B cells and myeloid cells, where it both amplifies and restrains signalling from the B-cell receptor and cytokine receptors. In chronic myeloid leukaemia, over-expression of LYN is a recognised mechanism of imatinib resistance that does not involve a BCR-ABL mutation, and the second-generation inhibitors dasatinib and bosutinib block LYN and other SRC kinases directly. LYN is also constitutively active in chronic lymphocytic leukaemia cells, contributing to their survival.
In plain words · LYN is a SRC-family kinase that sits under the B-cell receptor; dasatinib and bosutinib inhibit it alongside BCR-ABL, and LYN over-activity is one way chronic myeloid leukaemia escapes imatinib.
LYN is a SRC-family kinase that sits under the B-cell receptor; dasatinib and bosutinib inhibit it alongside BCR-ABL, and LYN over-activity is one way chronic myeloid leukaemia escapes imatinib.
A membrane-anchored non-receptor tyrosine kinase; it phosphorylates immunoreceptor tyrosine motifs to start SYK signalling and also activates inhibitory phosphatases, giving it dual roles.
No product in this corpus aims at LYN kinase yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Lineage antigen shared with normal bone marrow cells and lymphoid tissue cells: HPA finds the gene tissue enhanced in bone marrow, lymphoid tissue, and the 2 medicines aimed at it (Dasatinib, Bosutinib) act on the wild-type protein, so the normal lineage is hit too. HPA LYN: RNA tissue enhanced (bone marrow 70 nTPM, lymphoid tissue 80 nTPM); high antibody staining in 4 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas LYN tissue; Human Protein Atlas LYN pathology; Open Targets ENSG00000254087 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Yamanashi et al, Mol. Cell. Biol, 1987, "The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lck". Source.
A membrane-anchored non-receptor tyrosine kinase; it phosphorylates immunoreceptor tyrosine motifs to start SYK signalling and also activates inhibitory phosphatases, giving it dual roles.
RNA: tissue enhanced (bone marrow 70 nTPM, lymphoid tissue 80 nTPM), detected in all normal tissues.
Medium: Appendix, Bone marrow, Duodenum, Gallbladder, Lung.
No cancer stained high; medium in cervical cancer, endometrial cancer, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (LYN kinase under the B-cell receptor); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"LYN kinase" OR ABSTRACT:"LYN kinase" OR TITLE:"LYN" OR ABSTRACT:"LYN") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LYN kinase, not a curated reading list.
Shares SRC family kinases, Dasatinib.
Shares SRC family kinases, Dasatinib.
Shares Bosutinib, Dasatinib, Chronic myeloid leukaemia (CML).
Shares Chronic myeloid leukaemia (CML), Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
Shares Bosutinib, Dasatinib, BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML).
Shares Bosutinib, Dasatinib, Chronic myeloid leukaemia (CML).
Shares Bosutinib, Dasatinib, BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (CML).
Shares Chronic myeloid leukaemia (CML), Chronic lymphocytic leukaemia, Acute myeloid leukaemia.